Diabetes can lead to damage to blood vessels throughout the body, a condition known as diabetic vasculopathy. This vascular damage can impair blood flow to various organs, including the penis, leading to erectile dysfunction. Over time, the cumulative effects of diabetes-related vascular damage increase the likelihood of erectile dysfunction (ED) occurrence and severity. Diabetes often causes neuropathy, a condition characterized by nerve damage. Peripheral neuropathy affects the nerves outside the brain and spinal cord, including those that control erection and sexual arousal. As a result, diabetic neuropathy can disrupt the normal neurological pathways involved in achieving and maintaining an erection, contributing to ED.
Diabetes increases the risk of microvascular complications, such as retinopathy (eye damage) and nephropathy (kidney damage). These complications are indicative of systemic vascular damage and often occur concurrently with erectile dysfunction, further underscoring the relationship between diabetes and ED. Hence, the rising prevalence of diabetes contributes significantly to the growth of the erectile dysfunction market by increasing the incidence and severity of ED among affected individuals.
Access full Report @ https://www.databridgemarketresearch.com/jp/reports/uk-erectile-dysfunction-market
Data Bridge Market Research analyzes that the U.K. Erectile Dysfunction Market is expected to reach USD 451.63 million by 2031 from USD 260.49 million in 2023, growing with a CAGR of 7.2% in the forecast period of 2024 to 2031.
Key Findings of the Study
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Product Type (Drugs and Devices), Type (Secondary Erectile Dysfunction and Primary Erectile Dysfunction), Age Group (Less than 40, 40-60 and 60 - Above), End User (Hospital, Specialty Clinics, Home Healthcare, Ambulatory Surgical Centers andOthers), Distribution Channel (Direct Tenders, Retail Pharmacy, Online Pharmacy, Hospital Pharmacy and Others)
|
|
Countries Covered
|
U.K.
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Lupin (India), Coloplast Corp (Denmark), Viatris Inc. (U.S.), Augusta Medical Systems (U.S.), Bayer AG (Germany), Boston Scientific Corporation (U.S.), Eli Lily and Company (U.S.), Rigicon Inc. (U.S.), and Zephyr Surgical Implants (Switzerland) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, and regulatory framework
|
Segment Analysis
The U.K. erectile dysfunction market is segmented into five notable segments based on product type, type, age group, end user, and distribution channel.
- On the basis of product type, the market is segmented into drugs and devices
In 2024, the drugs segment is expected to dominate the U.K. Erectile Dysfunction Market
In 2024, the drugs segment is expected to dominate the market with a market share of 57.85% due to the increasing prevalence of chronic disorders.
- On the basis of type, the market is segmented into secondary erectile dysfunction, and primary erectile dysfunction
In 2024, the secondary erectile dysfunction segment is expected to dominate the U.K. Erectile Dysfunction Market
In 2024, the secondary erectile dysfunction segment is expected to dominate the market with a market share of 63.85% due to the increasing geriatric population.
- On the basis of age group, the market is segmented into less than 40, 40-60, and 60-above. In 2024, the less than 40 segment is expected to dominate the market with a market share of 53.85%
- On the basis of end user, the market is segmented into hospitals, specialty clinics, home healthcare, ambulatory surgical centers, and others In 2024, the hospitals segment is expected to dominate the market with a market share of 44.68%
- On the basis of distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2024, the direct tender segment is expected to dominate the market with a market share of 35.87%
Major Players
Data Bridge Market Research analyzes Pfizer Inc. (U.S.), Lupin (India), Coloplast Corp (Denmark), Viatris Inc. (U.S.), Augusta Medical Systems (U.S.) as the major companies operating in the U.K. erectile dysfunction market.
Market Developments
- In April 2021, as per NCBI, Zephyr Surgical Implants modified the pump-cylinders connection tube of ZSI 475 developing an additional reinforcement that should provide more sturdiness to the prosthesis. This has helped the company to strengthen its product portfolio.
- In November 2023, Rigicon, Inc. published a comprehensive study highlights Rigi10TM Malleable Penile Prosthesis safety outcomes implanted worldwide. The clinical study, titled “Safety Outcomes of the First Rigi10 Malleable Penile Prostheses Implanted Worldwide” provides a comprehensive evaluation of the safety of the Rigi10 Malleable Penile Prosthesis. This study underscores the device’s status as a reliable solution for patients seeking treatment for Erectile Dysfunction (ED). This has helped the company to strengthen its product portfolio for treating erectile dysfunction.
- In September 2018, Teva Pharmaceutical Industries Ltd. announced the exclusive first-to-file launch of a generic version of Cialis 1 (tadalafil) tablets (2.5 mg, 5 mg, 10 mg, 20 mg). This has helped the company to strengthen its product portfolio.
For more detailed information about the U.K. Erectile Dysfunction Market report, click here – https://www.databridgemarketresearch.com/jp/reports/uk-erectile-dysfunction-market
